Demographics of 40 treatment patients
| Total=40 | NEXC (n=17) | DTC (n=23) | p Value |
|---|---|---|---|
| Male (%) | 15 (88.2) | 14 (60.8) | 0.078 |
| Mean age starting treatment | 33.2 years | 33.5 years | 0.876 |
| Genotype 1 (%) | 5 (29.4) | 5 (21.7) | 0.716 |
| Genotype 2/3 (%) | 12 (70.5) | 18 (78.2) | 0.716 |
| HCV viral load <600 000 (%) | 10 (58.8) | 10 (43.4) | 0.523 |
| Fibrosis score <7 (%) | 13 (76.4) | 14 (60.8) | 0.332 |
| Outcomes end treatment=28 | n=10 | n=18 | |
| Completed treatment | 10 | 16 | 0.520 |
| Incomplete treatment/relapse | 0 | 1 | N/A |
| Incomplete non-responder | 0 | 1 | N/A |
| SVR data=22 | n=10 | n=12 | |
| SVR | 10 | 10 | 0.480 |
| Relapses | 0 | 0 | N/A |
| Sustained viral response (ITT) (%) | 10/10 (100) | 10/12 (83.3) |
DTC, Drug treatment centres; HCV, Hepatitis C virus; ITT, intention to treat; NEXC, needle exchange centres; SVR, sustained viral response.